Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre‐eclampsia and its complications

Rotchell, Y. E.; Cruickshank, J.K.; Griffiths, J.; Stewart, A.; Farrell, Barbara; Ayers, Sarah; Hennis, Anselm; Grant, Adrian; Duley, Lelia; Collins, Rory

doi:10.1111/j.1471-0528.1998.tb10088.x

Cited by 170 publications

(85 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Giving pregnant women aspirin during the antenatal period to prevent protein uric eclampsia resulted in low, but not statistically significant, rates of protein uric eclampsia. These results did not support the use of aspirin to prevent pre-eclampsia [28].…”

Section: Resultscontrasting

confidence: 44%

Maternal Mortality Interventions: A Systematic Review

Piane¹,

Clinton²

2014

OJPM

View full text Add to dashboard Cite

Background: In order to achieve the World Health Organization's Millennium Development Goal of reducing maternal mortality by three quarters by 2015, a strong global commitment is needed to address this issue in low-income nations where the risk to women is greatest. A comprehensive international effort must include provision of obstetric and general medical care as well as community-based interventions, with an emphasis on the latter in nations where the majority of women deliver babies at home without a trained attendant. Methods: This systematic analysis evaluates interventions published in Medline and CINAHL whose outcome measure is maternal mortality. Analysis includes components of the intervention, nation and maternal death rates. Results: Nine studies documented the effectiveness of various clinical and community-based interventions, including specific drug regimens and procedures, in reducing the risk of maternal death. Six studies reported interventions that did not significantly alter maternal mortality outcomes, and the intervention in one study demonstrated increased risk of maternal death. Conclusion: The dearth of evidence highlights the need for increased focus on translational research that bridges the gap between medical advances and community-based interventions that are feasible in low-income nations. This cannot be accomplished without a stronger commitment to reducing maternal mortality by global health practitioners and researchers.

show abstract

Section: Resultscontrasting

confidence: 44%

Maternal Mortality Interventions: A Systematic Review

Piane¹,

Clinton²

2014

OJPM

View full text Add to dashboard Cite

show abstract

“…Low dose aspirin does not decrease preeclampsia incidence in low risk nulliparous women (RR 0.93; 95% CI 0.81-1.08) [204,[214][215][216][217], although first trimester aspirin initiation is untested in RCTs. [221].…”

Section: Preventing Preeclampsia and Its Complicationsmentioning

confidence: 99%

RETIRED: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy

Magee

Pels

Helewa

et al. 2008

Journal of Obstetrics and Gynaecology Canada

421

218

View full text Add to dashboard Cite

“…1 More recent, larger, randomized controlled trials, usually performed in the general obstetric population, have not corroborated the benefits of ASA in the prevention of preeclampsia. [2][3][4] These studies concluded that the use of low-dose ASA during pregnancy was safe for the fetus, the newborn, and the mother, but the results did not support the routine prophylactic use of ASA for prevention of preeclampsia. Similar results were also found from a study involving women with pregestational insulin-treated diabetes mellitus, chronic hypertension, multifetal gestations, or a previous history of preeclampsia.…”

mentioning

confidence: 99%

Administration Time–Dependent Influence of Aspirin on Blood Pressure in Pregnant Women

2003

View full text Add to dashboard Cite

This study prospectively investigates the potential influence of low-dose aspirin on blood pressure in pregnant women who were at a higher risk of developing preeclampsia than that of the general obstetric population and who received aspirin at different times of the day according to their rest-activity cycle. A double-blind, randomized, controlled trial was conducted in 341 pregnant women (181 primipara) randomly assigned to 1 of 6 possible groups according to treatment (either placebo or aspirin, 100 mg/day, starting at 12 to 16 weeks of gestation) and the time of treatment: on awakening (time 1), 8 hours after awakening (time 2), or before bedtime (time 3). Blood pressure was automatically monitored for 48 consecutive hours every 4 weeks from the day of recruitment until delivery, as well as at puerperium. There was no effect of aspirin on blood pressure at time 1 (compared with placebo). A blood pressure reduction was highly statistically significant when aspirin was given at time 2 and, to a greater extent, at time 3 (mean reductions of 9.7/6.5 mm Hg in 24-hour mean for systolic/diastolic blood pressure at the time of delivery as compared with placebo given at bedtime). Differences in blood pressure among women receiving aspirin at different circadian times disappeared at puerperium (P>0.096). Results indicate a highly significant effect of aspirin on blood pressure that is markedly dependent on the time of aspirin administration with respect to the rest-activity cycle. Timed use of aspirin at low dose effectively contributes to blood pressure control in women at high risk for preeclampsia.

show abstract

Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre‐eclampsia and its complications

Cited by 170 publications

References 21 publications

Maternal Mortality Interventions: A Systematic Review

Maternal Mortality Interventions: A Systematic Review

RETIRED: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy

Administration Time–Dependent Influence of Aspirin on Blood Pressure in Pregnant Women

Contact Info

Product

Resources

About